Biotech Values

[ghmm]

I agree very interesting letter.

Not all members of the review team recommended the same regulatory action for flibanserin. Some concluded that its benefit–risk profile was unfavorable, even with the safety measures described here, and recommended against approval.5 In their view, ..

Not sure I am reading this right were there 5 people in the review against approval? I wonder if this gives hope to drisapersen. From the panel, I got the impression that a couple people were against approval. One could make the case for a (small) subset having a marginal treatment benefit. But its interesting the voting questions really didn't leave much room for panel to be positive.